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ABSTRACT
Conclusion: The management of Head and Neck Cancer of Unknown Primary (HNCUP) patients varies
both between centres within and also between the Nordic countries. This study contributes to a con-
tinuing discussion of how to improve the accuracy of diagnosis and quality of treatment of HNCUP
patients.
Objectives: The initiative for this study was based on the lack of common guidelines for diagnostic
procedures and for treatment of HNCUP patients in the Nordic countries constituting a region having a
rather homogeneous population.
Method: A structured questionnaire was sent to all university hospitals in the five Nordic countries.
Results: Four of the five Nordic countries use either national guidelines or specific protocols when han-
dling HNCUP. The main diagnostic tools are PET-CT, fine needle aspiration, endoscopic evaluation with
biopsies, and most often bilateral tonsillectomy. At 21 of 22 university hospitals the treatment decision
is made at a multidisciplinary conference. Three of seven Swedish centres use only radiotherapy or che-
moradiotherapy to treat Nþ HNCUP patients. Robotic surgery for biopsy of the tongue base is begin-
ning to become an alternative to targeted biopsies in Sweden and Finland. Narrow Band Imaging is
used only in Finland.
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Introduction
The definition of Head and Neck Cancer of Unknown
Primary (HNCUP) is the presence of a cervical lymph node
metastasis, for which therapy will be initiated even though
there is no specific evidence of a primary tumour. Extensive
clinical and radiological examinations are typically under-
taken before initiating treatment of HNCUP.
The incidence of HNCUP varies between 3–7% of all neck
lumps [1]. Many patients with an occult neck lump initially
diagnosed as a HNCUP are later identified with a primary
tumour. Waltonen et al. [2] found that nearly half of all pri-
mary tumours could be located using PET-CT and endoscopy.
A more recent report suggested that males constitute 72% of
all cases, the median age at onset being 55 years
(range¼ 42–87 years) [3]. Lymph node metastases located in
the supraclavicular fossa are frequently found to be of infra-
clavicular origin. Fine needle aspiration cytology and modern
molecular diagnostics have improved the assessment of cancer
of unknown primary. Accurate cytological diagnosis of
HNCUP is essential when choosing treatment modality, and
may become increasingly important in the HPV era [4,5].
It has been recognized that the diagnostic and treatment
modalities for HNCUP cases differ, and the present study is
the first attempt to systematically assess these differences in
the Nordic countries (Iceland, Norway, Denmark, Sweden,
and Finland). The recommendation is that the diagnostic
work-up should include both PET-CT and panendoscopy
with biopsies, including bilateral tonsillectomy [2,6]. Such an
action may offer the greatest likelihood of successfully identi-
fying an occult primary tumour. However, the availability of
PET-CT varies, as do the guidelines to use it.
Therapeutic approaches vary between centres, and treat-
ment modalities include surgery (lymph node excision or
neck dissection) with or without post-operative radiotherapy;
radiotherapy, alone or in combination with chemotherapy;
and radiotherapy, followed by surgery. In the early stage
(N1), neck dissection and radiotherapy seem to have similar
efficacy, whereas more advanced cases (N2, N3) necessitate a
combination of modalities [6]. One retrospective study con-
cluded that radiotherapy after neck dissection influenced the
overall survival [7], while another study suggested that IMRT
was the most beneficial radiotherapeutic approach [8].
Mistry et al. [9] reported that the overall 5-year survival was
better for HNCUP patients than for those with a known pri-
mary of comparable nodal stage. The overall 5-year survival
rate for the HNCUP group was found to be 55%. In
line with this, another study reported the 5-year survival rate
to be poorer among HNCUP patients where a primary
tumour was later detected, when compared with patients
having a persistent unknown primary (22% vs 52%).
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Significant prognostic factors in HNCUP were M-class,
smoking, alcohol consumption, and tonsillectomy [6].
The aim of this study was to compare diagnostic proce-
dures for and treatment of HNCUP at the head and neck
cancer centres of university hospitals in the five Nordic
countries.
Materials and methods
A multiple-choice questionnaire was designed in English by
the three authors, based on clinical experience and on appro-
priate current literature. The questionnaire was designed to
identify differences in diagnostic and treatment protocols
between the Nordic university hospitals. Questions regarding
outcome data were not included in this survey. The question-
naire was first tested at the Finnish university hospitals.
Consequently, physicians in Finland were used as a pilot
group in order to fine-tune the questions. After collecting
the comments from the Finnish university hospitals, the
questionnaire was revised accordingly by the authors. It now
comprised four parts (General information (2 questions),
Diagnostic procedures for HNCUP (11 questions), Treatment
of HNCUP (15 questions), Follow-up of HNCUP (3 ques-
tions)). Early in 2015 the revised questionnaire was sent to
all university hospitals in the Nordic countries (Figure 1),
representing a total population of 25 million people.
All university hospitals in Iceland (1), Sweden (7),
Norway (4), and Finland (5) kindly responded to the ques-
tionnaire. Denmark referred to their national guidelines for
HNCUP (www.DAHANCA.oncology.dk/Brows_Web_
Guidelines 2013), and a senior oncologist representing
DAHANCA completed the questionnaire accordingly.
Results
The management of HNCUP in Iceland and Sweden fol-
lowed a specific protocol based on local routines regarding
diagnostic procedure and treatment. Finland had national
Figure 1. Map showing all the university hospitals managing HNCUP included in this study; (1) Reykjavik, (2) Oslo, (3) Bergen, (4) Trondheim, (5) Tromsoe, (6)
Aalborg, (7) Aarhus, (8) Odense, (9) Herlev, (10) Copenhagen, (11) Lund, (12) Gothenburg, (13) Link€oping, (14) €Orebro, (15) Stockholm, (16) Uppsala, (17) Umeå, (18)
Helsinki, (19) Turku, (20) Tampere, (21) Kuopio, and (22) Oulu.
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guidelines for the treatment of head and neck cancer, but no
specific protocol for the diagnostics of HNCUP. In
Denmark, all centres applied the same national guidelines,
while, in Norway, two university hospitals used local proto-
cols, but no specific protocol was followed at the remaining
two centres. Patients were discussed at weekly
Multidisciplinary Tumour Board Meetings (MTBM) at all
sites except in Iceland.
In Sweden, two out of seven centres performed PET-CT
(Neck-Chest) as a primary imaging modality, and the
remaining centres performed conventional CT (Neck-Chest)
first. PET-CT was applied in all cases of HNCUP in
Denmark and Finland. In Iceland, PET-CT was unavailable.
In Norway two centres performed PET-CT in selected cases,
whereas the others used CT or MRI as their first choice of
imaging (Table 1).
Fine needle aspiration of the cervical mass was reportedly
carried out at all the participating centres in the Nordic
countries. The relation to HPV positivity was evaluated at all
centres (except in Iceland), with either p16 or PCR tech-
nique. EBV analysis was not a routine procedure in any of
the Nordic countries.
Panendoscopy, including bronchoscopy, esophagoscopy,
hypopharyngoscopy, and laryngoscopy, was performed at all
centres in Finland. In Iceland and Denmark, selective endos-
copies were performed, including hypopharyngoscopy and
laryngoscopy. In Sweden and Norway, local routines were
followed. Twenty-one of 22 centres performed endoscopic
procedures after the primary imaging.
Biopsy samples to detect a primary tumour were taken
from the tongue base, and epipharynx at all centres in
Denmark and Sweden. In Finland, Norway, and Iceland,
biopsies were taken according to their local routines.
In addition, tonsillectomy was performed either ipsi- or bilat-
erally at all centres. Most centres in Denmark (5/5), Sweden
(6/7), Norway (2/4), and Finland (4/5) performed bilateral
tonsillectomy as a standard procedure. The remaining five
centres performed bilateral tonsillectomy only in selected
cases.
Robotic surgery for biopsy of the tongue base was begin-
ning to become an alternative to targeted biopsies in Sweden
and Finland; the other countries had not yet introduced this
procedure into their protocol. In Finland, Narrow Band
Imaging was used during endoscopy to improve the informa-
tion where a biopsy should be taken.
In Sweden, three centres did not perform neck dissections
in Nþ HNCUP patients; instead, they used solely radiother-
apy or chemoradiotherapy. All other university hospitals
used radiotherapy or chemoradiotherapy combined with
neck dissection (Table 2).
Concerning follow-up, there was a disparity between
Finland and the other Nordic countries. In Finland, patients
treated for HNCUP were always monitored by the ENT sur-
geon, whereas the other Nordic countries most often used a
combined approach with visits alternatingly to ENT physi-
cians and oncologists. All Nordic patients were followed up
for 5 years after treatment. Most patients were initially seen
Table 1. Diagnostic procedures.
n %
Imaging modality
PET/CT 14 64
CT 7 32
MRI 1 5
Cytological method (needle aspiration)
Fine 22 100
Middle 0 0
Thick 0 0
Sites included for scopy
B, E, H, L 11 50
H, L 11 50
Biopsies
N, TB, T 17 77
N, TB 2 9
TB, T 2 9
T 1 5
Tonsillectomy
Unilateral 2 9
Bilateral 17 77
Bilateral in selected cases 3 14
Robotic surgery
Yes 5 23
No 17 77
Assessment under anaesthesia
Palpation 22 100
Narrow band imaging 5 23
Toluidine blue 0 0
B: bronchoscopy; E: esophagoscopy; H: hypopharyngoscopy;
L: laryngoscopy; N: nasopharynx; TB: tongue base; T: tonsil.
Table 2. Treatment.
n %
N1
Treatment
Surgery 5 23
RT 2 9
CRT 7 32
Surgeryþ RT 1 5
Surgeryþ CRT 7 32
Radiotherapy dose (Gy)
50–70 16 72
0ther 1 5
No RT 5 23
Radiotherapy of the neck*
Ipsilateral 5 24
Bilateral 11 52
No RT 5 24
N2
Treatment
Surgery — —
RT 2 9
CRT 2 9
Surgeryþ RT 7 32
Surgeryþ CRT 11 50
Radiotherapy dose (Gy)
50–70 21 95
0ther 1 5
Radiotherapy of the neck*
Ipsilateral 4 19
Bilateral 17 81
N3
Treatment
Surgery — —
RT 1 5
CRT 2 9
Surgeryþ RT 7 32
Surgeryþ CRT 12 54
Radiotherapy dose (Gy)
50–70 22 100
Radiotherapy of the neck*
Ipsilateral 2 10
Bilateral 19 90
*Data missing from one centre.
ACTA OTO-LARYNGOLOGICA 1161
by the primary treating centres, although a combination fol-
low-up was often organized, where every second visit was
performed by the referring hospital.
Discussion
The initiative to undertake this study was the lack of inter-
nationally accepted guidelines for diagnostic procedures and
treatment specifications for HNCUP patients. The study
was carried out at a tertiary hospital level in northern
Europe. The five Nordic countries combined have a rather
homogeneous population ( 25 million) regarding socioeco-
nomic and health-related factors. The countries’ healthcare
systems are similar, but there are still no unified treatment
protocols between them to tackle HNCUP. It, therefore,
seemed justified to evaluate the differences in existing
guidelines in this field. We chose to undertake the present
investigation, specifically the management of HNCUP, as
this would merely demonstrate the differences in guidelines
between the centres and not, for example, their availability
to use the various advanced reconstructive or oncological
techniques.
It is noteworthy that this survey covered all 22 university
hospitals in the five Nordic countries treating these patients.
This collaborative effort was made possible by the existing
membership network of the Scandinavian Society for Head
and Neck Oncology. The Society strives to promote collabor-
ation between head and neck surgeons and oncologists in the
Nordic countries, to stimulate multi-centre studies, and to
assist any advances toward unified treatment guidelines.
In the present study 14 of the 22 centres (64%) used
PET-CT as a primary imaging modality, although even PET-
CT is limited in its ability to detect small tumours. In a
meta-analysis comprising 13 studies, the sensitivity and spe-
cificity values of PET-CT were 0.84 and 0.96, respectively,
whereas those of conventional imaging were 0.63 and 0.96,
indicating that PET-CT may be more sensitive than conven-
tional imaging [10]. However, PET-CT may have a problem
with high false-positivity rates, due to relatively low specifi-
city, which is why multiple biopsies from suspicious sites are
recommended even after PET-CT [11]. Furthermore, it is
important that treatment initiation is not delayed due to
lacking availability of PET-CT [12].
Five centres in Sweden and Finland used robotic surgery
to improve the quality of biopsies from the tongue base. In a
study by Karni et al. [13] on the use of transoral laser micro-
surgery, a 94% primary tumour detection rate was demon-
strated, suggesting better specificity than with targeted
biopsies. To date, only Finnish university hospitals use
Narrow Band Imaging on a regular basis in order to opti-
mize the quality of the biopsy. In a recent review, Koivunen
et al. [14] reported an increased detection rate of the primary
tumour from 80% to 90%, following the introduction of
Narrow Band Imaging technique, combined with PET-CT
and trans-oral diagnostic procedures. Together, these studies
add valuable information to a growing body of evidence that
new diagnostic tools can improve diagnostic accuracy for pri-
mary tumours. MTBM is regarded as the gold standard for
treatment decision and optimization of patient care. Nguyen
et al. [15] conclude that, when all team members of the
MTBM take part in the treatment decision-making, it will be
based on performance status rather than inherent bias due to
age or perceived comorbidity. It should be noted that all the
Nordic university hospitals except one used MTBM as stand-
ard routine.
All countries except one either followed a specific protocol
or national guidelines for the management of HNCUP. Only
three centres treated patients with single modality radiother-
apy/chemoradiotherapy for Nþ necks, whereas the majority
combined neck dissection with radiotherapy/chemoradiother-
apy (86%).
The great majority of previous studies are based on retro-
spective data. Shoushtari et al. [16] found that pre-operative
IMRT (50–56Gy) followed by neck dissection gave excellent
overall and disease-free survival in N1–N2a disease (100%).
Furthermore, they found that patients with N2b–N3 disease,
with a significantly lower survival rate (66.7%, p¼ 0.017),
benefitted from concurrent chemotherapy, targeted thera-
peutic agents or accelerated radiotherapy regimens, in add-
ition to surgery. Cuaron et al. [17], however, found that
conventional radiotherapy produced excellent locoregional
control of HNCUP with acceptably low levels of late toxicity.
Chen et al. [18] reported that concurrent chemoradiotherapy
was associated with significantly increased toxicity without
definite benefit in overall survival or locoregional control in
the treatment of HNCUP. It has been suggested that post-
operative radiotherapy does not influence the rate of neck
relapse (p¼ 0.72), although when Issing et al. [7] compared
radiotherapy alone with neck dissection plus post-operative
radiotherapy, they found a significantly improved survival
rate in patients who underwent a diagnostic bilateral tonsil-
lectomy in addition to combined modality treatment. We
speculate that the reason why some centres do not perform
neck dissection could be that the occult primary tumour
often arises in the oropharyngeal region, which is included
in the radiotherapy field. Furthermore, the probability of an
HPV-positive tumour in this region is high [5] and the prog-
nostic implications of HPV-positive nodes in HNCUP are
similar to those in oropharyngeal primary cancers [4]. When
radiotherapy or chemo-radiotherapy is given, a small occult
primary tumour will be cured, and most likely never even be
detected during the follow-up. For this reason, some centres
maintain a conservative approach to surgery, sparing the
patient from surgical side-effects, even though a selective
neck dissection is associated with little post-operative
morbidity.
In Denmark, all centres have consented to follow their
national guidelines. During this study, Sweden published its
first national guidelines (Huvud och halscancer – Nationellt
vårdprogram 2015 Aug), although there is some scope for
local variation in the diagnostic work-up and treatment rec-
ommendations. In Finland all university hospitals follow
national guidelines for the treatment of head and neck can-
cer, but there are obvious variations regarding certain details,
as could be observed for the diagnosis of HNCUP in the cur-
rent study. The other Nordic countries adapt their manage-
ment according to local traditions.
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This survey contributes to an on-going discussion
intended to improve the quality of diagnosis and treatment
of HNCUP patients. In conclusion, the main diagnostic tools
currently used are PET-CT, fine needle aspiration, and endo-
scopic evaluation with biopsies from the nasopharynx,
tongue base, and bilateral tonsillectomy. Treatment modal-
ities include radiotherapy/chemoradiotherapy or neck dissec-
tion combined with radiotherapy/chemoradiotherapy. The
addition of chemotherapy is generally given when the patient
is fit to receive it and below 70 years of age.
The current study has established a suitable network and
platform in northern Europe based on a population exceed-
ing 25 million. Such a multi-centre network can be used to
compare survival data according to the given treatment, and
thereby facilitate future evaluation of survival differences
between the two major treatment groups: radiotherapy/che-
moradiotherapy, or surgery combined with radiotherapy/che-
moradiotherapy. Future multi-centre studies using this
starting point may hopefully improve our understanding of
the diagnostic tools, and how to manage HNCUP. Moreover,
this Nordic network could be used to establish common
guidelines for follow-up of patients with HNCUP, regarding
recurrence, late detection of primary tumours, and treatment
squealae.
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